Human Milk Oligosaccharides Market by Product (2'-Fucosyllactose(2'FL), 3'-Fucosyllactose, 3'-Sialyllactose ), Type, Application

Description

List of Tables

[191 Pages Report] The Human Milk Oligosaccharides Market size was estimated at USD 297.90 million in 2023 and expected to reach USD 323.44 million in 2024, at a CAGR 9.72% to reach USD 570.55 million by 2030.

Human milk oligosaccharides (HMOs) are a mixed group of complex carbohydrates naturally present in human breast milk. They represent human milk's third enormous solid component after lactose and fat. As non-digestible food ingredients, HMOs serve multiple functions that contribute to the advantageous effects of human milk on infant health and development. HMOs play a critical role in developing an infant's gut microbiota, acting as prebiotics by selectively encouraging the development of beneficial bacteria, including Bifidobacteria and Lactobacillus. This helps establish a healthy intestinal environment that supports nutrient absorption and protects against pathogenic bacteria. Additionally, their utilization extends into functional foods and dietary supplements owing to their prebiotic and anti-pathogenic properties. HMOs are also studied for therapeutic potentials in gastroenterology, immunology, and oncology. The market is driven by the scientific consensus on the advantages of breastfeeding and the rising awareness of the benefits of HMOs. Technological advancements in the synthesis and extraction of HMOs contribute to market expansion. A growing infant formula industry, rising health concerns, and increasing purchasing power contributed significantly to the HMO market's growth. However, the growth of HMOs is hampered by high research and development costs associated with HMO production, regulatory challenges, the requirement for extensive safety evaluations before approvals, and the complexity of synthesizing HMOs that are identical to the ones found in human milk. On the other hand, the latest potential opportunities in the HMO market include the development of new and more cost-effective extraction and synthesis methods for a broader range of HMO compounds. Another area of opportunity lies in expanding the applications beyond dietary supplements and infant nutrition, particularly in gut health, immunity boosters, and therapeutic agents. Collaboration with healthcare institutions for clinical trials and academic institutions for research can create opportunities for market players.

KEY MARKET STATISTICS
Base Year [2023]	USD 297.90 million
Estimated Year [2024]	USD 323.44 million
Forecast Year [2030]	USD 570.55 million
CAGR (%)	9.72%

Product: Increasing preference for 2'-Fucosyllactose(2'FL) due to its abundance in human milk and proven health benefits

2'-Fucosyllactose (2'FL) is the most abundant oligosaccharide present in human milk, particularly in the milk of mothers who are secretors of the H antigen. It is reputed for its prebiotic effects, such as supporting a healthy gut microbiota and stimulating the immune system. Consequently, the need for 2'FL is paramount in infant formula to emulate some of these benefits found in breast milk. 3'-Fucosyllactose (3'FL) is increasingly recognized for its role in developing the immune system and modulating the gut environment. It is considered a significant HMO for infant nutrition due to its potential role in protecting against pathogens. Demand for 3'FL is rising in the development of next-generation infant formula and child nutritional products. 3'-Sialyllactose (3'SL) contains sialic acid, crucial for brain development and cognitive function. There is a preference for 3'SL in products promoting infant neurological development. Another sialic acid-containing oligosaccharide, 6'-Sialyllactose (6'SL), is vital for brain development and may have roles in modulating cell adhesion and signaling. Its inclusion in infant nutrition products is highly valued for these reasons. Lacto-N-neotetraose (LNnT) has garnered interest due to its structural similarity with critical cell surface glycan structures, potentially playing a part in preventing pathogen adhesion in the gut. Its application extends to both infant formulas and dietary supplements. Lacto-N-tetraose (LNT) is crucial for infant gut maturation and the development of the microflora. While its market penetration is less than that of other HMOs, interest in LNT is increasing, particularly for its role in supporting the immune system and preventing gastrointestinal infections.

Application: Growing application of HMOs for replicating the complex health-sustaining properties of breast milk for infants

HMOs are increasingly incorporated into functional food and dietary supplements owing to their multiple health benefits. HMOs are known to support digestive health, enhance immune function, and potentially lower the danger of certain infections. They are prebiotic substances that foster a beneficial environment for gut microbiota, which is crucial for overall wellness. The need for HMOs in functional foods and supplements is particularly strong among consumers looking to improve gut health and boost immunity. The most prominent application of HMOs is in infant formula, given their role in mimicking the composition of human breast milk. These complex carbohydrates are the third-most abundant solid component in human milk and are crucial for the development of an infant's gut flora and immune system. In the segment of infant formula, HMOs address the needs of infants who may not have access to breast milk or require supplemental feeding. They are designed to support infants' brain development, digestive health, and immunity. In the laboratory research context, HMOs are valuable for their contribution to the scientific understanding of human milk, gastroenterology, neonatology, and immunology. Research applications include studies on prebiotic and probiotic effects, investigation into preventing necrotizing enterocolitis, and understanding the role of oligosaccharides in brain development and cognition. This need-based preference is driven primarily by academic, governmental, and industrial research institutions seeking to expand the frontier of knowledge on HMOs. Each HMO application segment addresses a different need and operates within unique market dynamics. In functional food and supplements, the focus is on preventive health care and supplementing diets with additional nutritional benefits. In infant formulas, the emphasis is on replicating breast milk's complex health-sustaining properties for infants who cannot breastfeed. On the other hand, laboratory research is more about pushing the boundaries of scientific knowledge with less immediate commercial application.

Regional Insights

The United States holds a significant share of the global HMOs market, driven by robust R&D initiatives and consumer awareness regarding infant nutrition. The region has witnessed growing demand for HMO-enhanced infant formula, attributed to the increasing need for nutritionally rich alternatives to breast milk. In Canada, consumer interest in advanced nutritional compositions for infants, including HMO-supplemented formulas, is growing. However, the market is just budding, and consumer purchasing behavior tends to lean toward trusted brands and scientifically backed products. The market for HMOs in South America is in a developing stage. Countries such as Brazil and Argentina are increasingly demanding advanced infant nutrition products. The European Union presents a mature market for HMOs, with a strong focus on infant nutrition and well-being. Countries such as Denmark and Germany are leading in terms of HMO research and production. EU regulations are stringent on product safety and quality, requiring companies to undergo rigorous evaluations. This has led to a customer base that is well-informed and discerning. While the market for HMOs is less pronounced in the Middle East and Africa, there is a noticeable increase in demand tied to rising incomes and an emerging middle class. Interest in advanced nutritional formulas for infants is growing, although the awareness and understanding of HMOs benefits are still developing. The APAC region is witnessing a rapid increase in demand for HMOs, particularly in countries such as India, China, and Japan. China has quickly become a primary market for HMOs in Asia, with national policies endorsing breastfeeding and higher-quality infant formula. Japan is known for its high standards in food safety and quality, which extends to the HMO market. Japanese consumers are health-conscious and show readiness to adopt scientifically-supported products, contributing to a steady demand for HMO-supplemented formulas. India is seen as an emerging market with vast potential for HMOs due to its large population and increasing focus on nutritional security. The awareness of the importance of early childhood nutrition is on the rise, and companies aim to capture this market by scaling up investment and promoting informed consumer behavior.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Human Milk Oligosaccharides Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Human Milk Oligosaccharides Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Human Milk Oligosaccharides Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Advanced Protein Technologies Corp., Agilent Technologies, Inc., BASF SE, Biosynth AG, Chr. Hansen Holding A/S, Conagen, Inc., Dextra Laboratories Ltd, DuPont de Nemours, Inc., Elicityl SA, Glycosyn LLC, Gnubiotics Sciences SA, Inbiose NV, Kirin Holdings Company, Limited, Koninklijke DSM N.V., Laita Nutrition, Lonza Group AG, Nestle S.A., Roquette Freres, Royal FrieslandCampina N.V., Tate & Lyle PLC, TurtleTree, and ZuChem, Inc..

Market Segmentation & Coverage

This research report categorizes the Human Milk Oligosaccharides Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- 2'-Fucosyllactose(2'FL)
- 3'-Fucosyllactose (3'FL)
- 3'-Sialyllactose (3'SL)
- 6'-Sialyllactose (6'SL)
- Lacto-n-neotetraose (LNnT)
- Lacto-n-tetraose (LNT)

Type
- Acidic
- Neutral

Application
- Functional Food & Supplements
- Infant Formulas
- Laboratory Research

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Human Milk Oligosaccharides Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Human Milk Oligosaccharides Market?

3. What are the technology trends and regulatory frameworks in the Human Milk Oligosaccharides Market?

4. What is the market share of the leading vendors in the Human Milk Oligosaccharides Market?

5. Which modes and strategic moves are suitable for entering the Human Milk Oligosaccharides Market?

Product Code: MRR-433C4187C520

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increase HMO Application in Infant Formula and Functional Food owing to the Nutritional Value
  - 5.1.1.2. Rising Awareness Regarding the Concerns Related to Child Malnourishment and Mortality all Over the Globe
  - 5.1.1.3. Increasing Demand for HMOs Supplements in Adults
- 5.1.2. Restraints
  - 5.1.2.1. High Cost associated with the R&D and Large Production
- 5.1.3. Opportunities
  - 5.1.3.1. Advancement in the Product Line of HMOs
  - 5.1.3.2. Rising Demand for Nutritional Supplements from China and India
- 5.1.4. Challenges
  - 5.1.4.1. Regulatory Framework Specific to Countries and Regions
5.2. Market Segmentation Analysis
- 5.2.1. Product: Increasing preference for 2'-Fucosyllactose(2'FL) due to its abundance in human milk and proven health benefits
- 5.2.2. Application: Growing application of HMOs for replicating the complex health-sustaining properties of breast milk for infants
5.3. Market Trend Analysis
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
5.9. Client Customization

6. Human Milk Oligosaccharides Market, by Product

6.1. Introduction
6.2. 2'-Fucosyllactose(2'FL)
6.3. 3'-Fucosyllactose (3'FL)
6.4. 3'-Sialyllactose (3'SL)
6.5. 6'-Sialyllactose (6'SL)
6.6. Lacto-n-neotetraose (LNnT)
6.7. Lacto-n-tetraose (LNT)

7. Human Milk Oligosaccharides Market, by Type

7.1. Introduction
7.2. Acidic
7.3. Neutral

8. Human Milk Oligosaccharides Market, by Application

8.1. Introduction
8.2. Functional Food & Supplements
8.3. Infant Formulas
8.4. Laboratory Research

9. Americas Human Milk Oligosaccharides Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Human Milk Oligosaccharides Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Human Milk Oligosaccharides Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Nestle launches its first product with HMOs in China, reinforcing its global leadership in nutrition science
- 12.3.2. Firmenich Completes Merger Of Equals With Dsm
- 12.3.3. Novozymes Agrees to Buy Chr. Hansen in USD 12.3 Billion Deal

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio